In the News

The  World Health Organization (WHO) Guideline Development Group is conditionally recommending the antiviral drug molnupiravir for patients with non-severe coronavirus disease 2019 (COVID-19) who are at highest risk of hospitalisation.

Patients who are at highest risk of hospitalisation...

By Denise Baez

Treatment of symptomatic coronavirus disease 2019 (COVID-19) with nirmatrelvir plus ritonavir resulted in a 89% reduced risk of progression to severe COVID-19, compared with placebo, without evident safety concerns, according to a study published in The New England...

Heart function recovery returned within 3 months in children who developed coronavirus disease 2019 (COVID-19)-related multisystem inflammatory syndrome (MIS-C), according to a study published in the Journal of the American Heart Association Report.

This study details the...

N95 respirators reprocessed with vaporised hydrogen peroxide maintained their function and effectiveness through 25 cycles of reuse, according to a study published in the American Journal of Infection Control.

In keeping with guidance from the Centers for Disease Control and...

The US Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for molnupiravir for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and...

The US Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for

nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use (Paxlovid) for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults and paediatric patients aged 12 years...

By Denise Baez

People aged 50 years and older who received a booster at least 5 months after a second dose of the BNT162b2 vaccine had 90% lower mortality due to coronavirus disease 2019 (COVID-19) than participants who did not receive a booster, according to a study published in The...

By Denise Baez

Three separate studies published in The New England Journal of Medicine show that immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) significantly diminishes between 2 to 6 months after the second dose of the BNT162b2 mRNA vaccine.

...

An observational study of patients with alcohol use disorder (AUD) admitted to intensive care units throughout the United States found that almost half of the people evaluated did not receive thiamine supplementation.

Patients with AUD who were admitted for reasons other than alcohol...

Insomnia may be a potential risk factor for intracranial aneurysm and aneurysmal subarachnoid haemorrhage, along with more well known risk factors of smoking and high blood pressure, according to a study published in the ...

Pages